Trials / Active Not Recruiting
Active Not RecruitingNCT07413679
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
An Observational Study to Assess Long-Term Safety of Danicopan Add-on Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a noninterventional cohort study using primary and secondary data from the International PNH Interest Group (IPIG) PNH registry. It is designed to characterize the long-term safety and tolerability of danicopan as add-on therapy to eculizumab or ravulizumab in adult participants with PNH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Danicopan | Participants will receive Danicopan as an add-on therapy. |
Timeline
- Start date
- 2025-08-18
- Primary completion
- 2029-07-01
- Completion
- 2029-07-01
- First posted
- 2026-02-17
- Last updated
- 2026-02-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07413679. Inclusion in this directory is not an endorsement.